- Global Pharma News & Resources

Overactive Bladder Treatment Market Growing With Highest Demand by 2027 – with Janssen Pharmaceuticals Inc., Accord Healthcare Inc., Mylan Pharmaceuticals Inc., Barr Laboratories Inc. etc

SEATTLE, April 09, 2021, (PHARMIWEB) — Global Overactive Bladder Treatment Market

Overactive bladder is a common medical condition, in which there arises a sudden urge for urination at any time. Overactive bladder is sometimes coupled with urine leakage, which is a condition called urinary incontinence. Millions of people across the globe suffer from overactive bladder and it is more common among the older generation. Urine leakage and frequent urination are the main symptoms of overactive bladder. The frequency of urination in the patient is more than eight times a day. Moreover, frequent urination during sleep hours is common in such patients. Overactive bladder is generally diagnosed through tests, such as urine culture, bladder scan, cystoscopy, or urodynamic testing.

A sample of this report is available upon request @

A robust drug pipeline of drugs, which are undergoing phase II and phase III clinical trials, is soon expected to be available across the market, and this is expected to drive the global overactive bladder treatment market growth. However, alternate therapies, such as the neuromodulation therapy, which includes sacral neuromodulation and percutaneous tibial nerve stimulation to deliver electric impulse to nerve, are projected to hinder the global market growth.

Global Overactive Bladder Treatment Market Dynamics

High prevalence of overactive bladder is expected to propel the global overactive bladder treatment market growth over the forecast period. Moreover, escalating awareness about the importance of diagnosis and treatment of the disease is a key factor leading to an increased number of patients being treated for the condition. Furthermore, increasing number of drug development programs for overactive bladder is expected to fuel the overactive bladder treatment market growth, by adding new drug in the market. Currently, generic drugs, such as cholinergic receptor inhibitors, are available for the treatment of this condition. Therefore, development and approval of new drug entity with a better drug profile, are likely to boost the global market growth.

For instance, in 2018, Urovant Sciences, a biopharmaceutical company that focuses on developing novel therapies for urologic conditions, entered the phase III clinical trial for its drug ‘Vibegron’, which is an oral Beta-andrenergic agonist indicated for the overactive bladder treatment. Furthermore, Taris Biomedical LLC entered the phase II clinical trials for its drug candidate TAR-302 for the treatment of overactive bladder. TAR 302 is a trospium chloride-based continuous local therapy, which is expected to efficiently aid in the treatment of overactive bladder, with just a few side effects.

The key players operating in the global overactive bladder treatment market are focused on the development of a wide range of combinational therapies. For instance, in 2017, Astellas Pharma, Inc. received supplemental New Drug Application (sNDA) from FDA for conditional therapy of mirabegron and solifenacin succinate for the treatment of urinary incontinence.

Global Overactive Bladder Treatment Market – Regional Analysis

The North America overactive bladder treatment market holds a dominant position, owing to the high prevalence of overactive bladder across the region. According to the 2016 review published in the journal Current Bladder Dysfunction Reports, millions of people suffer from overactive bladder in the U.S. each year and there has been a continuous increase in the cost of overactive bladder treatments over the recent years. However, surging awareness about the disease in Asia Pacific regions is expected to boost the overactive bladder treatment market growth in the region in the upcoming years.

Buy Now this Premium Report to Grow your Business @

Global Overactive Bladder Treatment Market – Competitive Analysis

The key players operating in the global overactive bladder treatment market include Janssen Pharmaceuticals Inc., Accord Healthcare Inc., Mylan Pharmaceuticals Inc., Barr Laboratories Inc. (a subsidiary of Teva Pharmaceuticals), Alembic Pharmaceuticals Ltd., Pfizer Inc., Astellas Pharma Inc., Endo International PLC, and Invagen Pharmaceuticals Inc.

These players have been focusing on leveraging their expertise to develop novel treatment therapies for the disease. For instance, in 2017, UroGen Pharma Ltd., a clinical-stage biopharmaceutical company, in collaboration with Allergan Pharmaceuticals International Limited, entered into the phase II clinical trial for RTGel, in combination with BOTOX, for the overactive bladder treatment. RTGel is a hydrogel-based proprietary formulation of UroGen Pharma Ltd.

Market Taxonomy

On the basis of drug type:

  • Anticholinergics
    • Oxybutynin
    • Darifenacin
    • Fesoterodine
    • Solifenacin
    • Tolterodine
    • Trospium
  • Mirabegron
  • Botox

On the basis of route of administration:

  • Topical
  • Oral
  • Intravenous

By distribution channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By region:

  • North America
  • Europe
  • Latin America
  • Asia Pacific
  • Middle East
  • Africa
About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website –


Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837

Editor Details

  • Company:
    • CDN Newswire
Last Updated: 09-Apr-2021